Table 2.
Demographic and clinical data of studied patients.
| Nr | Sex | Onset | Age of Assessment |
Disease Duration |
RE | LE | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| BCVA (LogMAR) |
VF | EZ | BCVA (LogMAR) |
VF | EZ | |||||
| 1 | M | 25 | 46 | 21 | −0.50 | 21 | 0 | −1.0 | 25 | 0 |
| 2 | F | 42 | 75 | 33 | −2.70 | 0 | 0 | −0.50 | 10 | 0 |
| 3 | M | 39 | 43 | 4 | 0.00 | 124 | 5251 | −0.10 | 131 | 5053 |
| 4 | M | 18 | 42 | 24 | −3.70 | 0 | 0 | −3.70 | 0 | 0 |
| 5 | M | 17 | 30 | 13 | −0.50 | 50 | 3321 | −0.18 | 43 | 641 |
| 6 | M | 22 | 26 | 4 | 0.00 | 129 | 3576 | 0.00 | 133 | 3525 |
| 7 | F | 20 | 62 | 42 | −0.92 | 17 | 2084 | −0.80 | 18 | 1337 |
| 8 | F | 14 | 26 | 12 | 0.00 | 79 | 2197 | 0.00 | 80 | 2577 |
| 9 | F | 25 | 49 | 24 | −0.70 | 120 | 2085 | −0.50 | 107 | 1556 |
| 10 | F | 25 | 46 | 21 | −0.30 | 62 | 1549 | −0.30 | 60 | 1581 |
| 11 | F | 43 | 68 | 25 | −2.70 | 17 | 0 | −2.70 | 0 | 0 |
| 12 | M | 39 | 49 | 10 | −0.50 | 30 | 4075 | −0.40 | 16 | 4313 |
| 13 | F | 30 | 65 | 35 | −0.70 | 18 | 0 | −0.50 | 16 | 0 |
| 14 | F | 30 | 51 | 21 | −0.10 | 22 | 2018 | 0.00 | 25 | 2448 |
| 15 | M | 14 | 69 | 55 | −3.70 | 0 | 0 | −3.70 | 0 | N/A |
| 16 | F | 26 | 51 | 25 | −0.30 | 19 | 0 | −0.18 | 20 | 3395 |
| 17 | M | 45 | 61 | 16 | −2.70 | 0 | 0 | −2.70 | 0 | 0 |
Legend: F, female; M, male; RE, right eye; LE, left eye; BCVA, best corrected visual acuity; VF, visual field; EZ, ellipsoid zone.